Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARAVNASDAQ:ENVBNASDAQ:GLMDOTCMKTS:KAYS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARAVARAVIVE$0.04$0.04$0.04▼$2.46$2.95MN/AN/AN/AENVBEnveric Biosciences$1.26+0.4%$1.27$1.01▼$11.55$3.10M0.54773,070 shs34,940 shsGLMDGalmed Pharmaceuticals$1.81-0.3%$1.51$1.15▼$23.80$2.98M0.61.32 million shs107,596 shsKAYSKaya$0.03-9.6%$0.04$0.02▼$0.05$752K0.2710,244 shs14,251 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARAVARAVIVE0.00%0.00%0.00%0.00%0.00%ENVBEnveric Biosciences+1.63%+0.81%+1.63%-2.34%-84.91%GLMDGalmed Pharmaceuticals+1.69%0.00%+24.83%+23.97%-49.55%KAYSKaya-9.60%-0.59%-10.79%-8.38%-20.79%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARAVARAVIVEN/AN/AN/AN/AN/AN/AN/AN/AENVBEnveric Biosciences3.1961 of 5 stars3.54.00.00.03.30.01.3GLMDGalmed Pharmaceuticals2.0078 of 5 stars0.05.00.00.02.72.50.6KAYSKayaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARAVARAVIVE 0.00N/AN/AN/AENVBEnveric Biosciences 3.00Buy$10.00696.81% UpsideGLMDGalmed Pharmaceuticals 2.00HoldN/AN/AKAYSKaya 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest KAYS, ENVB, GLMD, and ARAV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/4/2025GLMDGalmed PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARAVARAVIVE$9.14M0.32N/AN/AN/A∞ENVBEnveric BiosciencesN/AN/AN/AN/A$2.35 per shareN/AGLMDGalmed PharmaceuticalsN/AN/AN/AN/A$9.87 per shareN/AKAYSKaya$10K75.16N/AN/A($0.77) per share-0.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARAVARAVIVE-$76.32MN/A0.00∞N/AN/AN/AN/AN/AENVBEnveric Biosciences-$9.57M-$38.38N/AN/AN/AN/A-250.28%-195.57%8/11/2025 (Estimated)GLMDGalmed Pharmaceuticals-$7.52M-$16.66N/A∞N/AN/A-32.21%-28.59%8/26/2025 (Estimated)KAYSKaya-$2.08M-$0.08N/A∞N/AN/AN/A-1,044.25%8/13/2025 (Estimated)Latest KAYS, ENVB, GLMD, and ARAV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2025Q1 2025GLMDGalmed PharmaceuticalsN/A-$0.62N/A-$0.62N/AN/A5/21/2025Q1 2025KAYSKayaN/A-$0.04N/A-$0.04N/A$0.01 million5/14/2025Q1 2025ENVBEnveric Biosciences-$3.45-$1.22+$2.23-$1.22N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARAVARAVIVEN/AN/AN/AN/AN/AENVBEnveric BiosciencesN/AN/AN/AN/AN/AGLMDGalmed PharmaceuticalsN/AN/AN/AN/AN/AKAYSKayaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARAVARAVIVEN/AN/AN/AENVBEnveric BiosciencesN/A4.084.08GLMDGalmed PharmaceuticalsN/A9.029.02KAYSKayaN/A0.010.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARAVARAVIVE35.80%ENVBEnveric Biosciences13.82%GLMDGalmed Pharmaceuticals76.14%KAYSKayaN/AInsider OwnershipCompanyInsider OwnershipARAVARAVIVE60.40%ENVBEnveric Biosciences1.10%GLMDGalmed Pharmaceuticals19.80%KAYSKaya23.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARAVARAVIVE2073.56 million29.13 millionNo DataENVBEnveric Biosciences202.47 million2.45 millionNot OptionableGLMDGalmed Pharmaceuticals201.65 million1.33 millionNot OptionableKAYSKaya422.17 million16.96 millionNot OptionableKAYS, ENVB, GLMD, and ARAV HeadlinesRecent News About These CompaniesKaya Holdings, Inc. (KAYS) - Yahoo FinanceJune 27, 2025 | finance.yahoo.comLolong 2: Umepekto kaya kay Lolong ang alindog ni Aya? (Episode 86)May 23, 2025 | msn.comKaya Holdings Delays 10-Q FilingMay 14, 2025 | tipranks.comRicky Lee reflects on writers being 'invisible' in Philippine cinema: 'Wala sa trailers, wala sa credits'May 2, 2025 | gmanetwork.comGKaya Holdings, Inc.: The Sacred Mushroom, Oregon's Premier Psilocybin Treatment Center Introduces "Synergy by Design" Journey Customization ProgramJanuary 16, 2025 | finanznachrichten.deKaya Holdings, Inc. (OTCQB:KAYS): The Sacred Mushroom, Oregon's Premier Psilocybin Treatment Center Introduces "Synergy by Design" Journey Customization ProgramJanuary 16, 2025 | accessnewswire.comA'I feel blessed every day': Kaya's Kitchen in Belmar celebrates 20 years in businessJanuary 13, 2025 | usatoday.comStreetsboro police K-9 killed in accident, community demands answersJanuary 9, 2025 | msn.comStreetsboro K-9 dies after being hit by car: ‘Heartbreaking and horrific’January 8, 2025 | msn.comStreetsboro K-9 dies after being hit by car: 'Heartbreaking and horrific'January 8, 2025 | msn.comStreetsboro police dog struck, killed by vehicleJanuary 8, 2025 | msn.comPolice K9 dies after car hits him on Ohio roadJanuary 8, 2025 | msn.comOfficers mourn K-9 hit and killed by car while stretching his legsJanuary 8, 2025 | mysuncoast.comM'Kaya didn't come back to him': Streetsboro police mourning after death of K-9 officerJanuary 8, 2025 | msn.comStreetsboro police K-9 struck, killed by vehicle Tuesday afternoonJanuary 7, 2025 | news5cleveland.comNStreetsboro Police K-9 struck and killed on State Route 303January 7, 2025 | msn.com'Heartbreaking and horrific accident': Streetsboro police K-9 dies after being hit by car while on dutyJanuary 7, 2025 | wkyc.comWHearts Melt at What Turns 13-Year-Old Basset Hound Into 'a Puppy Again'December 26, 2024 | msn.comKaya Holdings, Inc. and the Sacred Mushroom(TM) Psilocybin Treatment Facility Announce Inaugural Open House and New Series of Low-Dose Psilocybin SessionsDecember 23, 2024 | accesswire.comAIt's Showtime: 'And The Breadwinner Is' cast, tutumpak kaya ang hula? (And The Breadwinner Is)December 19, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKAYS, ENVB, GLMD, and ARAV Company DescriptionsARAVIVE NASDAQ:ARAV$0.04 0.00 (0.00%) As of 07/2/2025Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.Enveric Biosciences NASDAQ:ENVB$1.25 +0.01 (+0.40%) As of 03:18 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.Galmed Pharmaceuticals NASDAQ:GLMD$1.80 -0.01 (-0.28%) As of 03:33 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.Kaya OTCMKTS:KAYS$0.03 0.00 (-9.60%) As of 07/2/2025 03:45 PM EasternKaya Holdings, Inc., a vertically integrated legal cannabis enterprise, engages in the operation of psychedelic treatment clinics and medical cannabis dispensaries primarily in the United States. It offers a range of cannabis products, including flower, oils, vape cartridges and cannabis infused confections, baked goods, and beverages. The company also operates retail outlets under the Kaya Shack brand name, as well as offers strain specific cannabis cigarettes under the Kaya Buddies name, and strains of cannabis under the Kaya Farms name. In addition, it is involved in the development of a psychedelic treatment center under The Sacred Mushroom name, that provides its guests access to psilocybin treatments, located in Portland, Oregon. The company was formerly known as Alternative Fuels America, Inc. and changed its name to Kaya Holdings, Inc. in April 2015. Kaya Holdings, Inc. is headquartered in Fort Lauderdale, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
